{"id":"W2951196418","doi":"10.1136/annrheumdis-2019-eular.1474","title":"FRI0430 IXEKIZUMAB IMPROVES THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS REGARDLESS OF SEX, DURATION OF DISEASE, OR BODY MASS INDEX IN TWO RANDOMIZED, PHASE 3 CLINICAL TRIALS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Women's College Hospital","funders":"UCB Pharma; British Heart Foundation; Prothena; Gilead Sciences; Novo Nordisk; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ixekizumab; Internal medicine; Psoriatic arthritis; Placebo; Rheumatology; Psoriasis; Body mass index; Psoriasis Area and Severity Index; Arthritis; Secukinumab; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003347115,0.001623789,0.003446246,0.0004292265,0.0005783802,0.00122723,0.0009155087,0.001911039,0.005468222],"category_scores_gemma":[0.002692411,0.0006889569,0.004073872,0.0004885321,0.0009425019,0.0009308977,0.0003628434,0.003083877,0.0007955881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007572226,"about_ca_system_score_gemma":0.001138519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064873,"about_ca_topic_score_gemma":0.003702115,"domain_scores_codex":[0.9989256,0.0005390625,0.0001027774,0.0001719807,0.000105416,0.000155169],"domain_scores_gemma":[0.9986624,0.0005109794,0.0003239086,0.0001117291,0.0001013817,0.0002895976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9320634,0.008398103,0.001038537,0.002451377,0.005503717,0.00007698125,0.0001003558,0.0004915775,0.004455223,0.0001414086,0.002145357,0.043134],"study_design_scores_gemma":[0.949771,0.045229,0.002428125,0.00007602015,0.001108848,0.00005496107,0.0000225081,0.0002000341,0.0003356874,0.00009534908,0.000659121,0.00001934788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9525352,0.03453711,0.001187105,0.001491542,0.001031976,0.003437667,0.001840935,0.0002412886,0.003697067],"genre_scores_gemma":[0.9753313,0.01178804,0.002371859,0.002319473,0.0006125412,0.002678352,0.001578768,0.00003525643,0.00328448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005468222,"threshold_uncertainty_score":0.01829302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05561096646374437,"score_gpt":0.4066431658645649,"score_spread":0.3510321994008206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}